Dataset Information

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

ABSTRACT: A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I(2) = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.

SUBMITTER: Danese E

PROVIDER: S-EPMC3731755 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Danese E E Montagnana M M Johnson J A JA Rettie A E AE Zambon C F CF Lubitz S A SA Suarez-Kurtz G G Cavallari L H LH Zhao L L Huang M M Nakamura Y Y Mushiroda T T Kringen M K MK Borgiani P P Ciccacci C C Au N T NT Langaee T T Siguret V V Loriot M A MA Sagreiya H H Altman R B RB Shahin M H A MH Scott S A SA Khalifa S I SI Chowbay B B Suriapranata I M IM Teichert M M Stricker B H BH Taljaard M M Botton M R MR Zhang J E JE Pirmohamed M M Zhang X X Carlquist J F JF Horne B D BD Lee M T M MT Pengo V V Guidi G C GC Minuz P P Fava C C

Clinical pharmacology and therapeutics 20121107 6

A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygo ...[more]

PMID: 23132553

Similar Datasets

Project description:BACKGROUND:The anticoagulation of atrial fibrillation catheter ablation during the perioperative stage does matter and should be treated with discretion. We aimed to assess impact of three important genes participating in vitamin K cycle (i.e. VKORC1 rs9923231, CYP4F2 rs2108622 and NQO1 rs1800566) on the daily stable warfarin dose requirement in Sichuan Han Chinese patients with catheter ablation of atrial fibrillation. METHODS:A total of 222 atrial fibrillation patients taking stable warfarin therapy after catheter ablation operation were enrolled in this study. The study population included had high (?2) risk according to the CHA2DS2-VASc risk score. Genotypes of VKORC1 rs9923231, CYP4F2 rs2108622 and NQO1 rs1800566 were analyzed by using the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP). Multiple linear regression analysis was applied to depict the impact of VKORC1 rs9923231, CYP4F2 rs2108622 and NQO1 rs1800566 on the daily stable warfarin dose requirement. RESULTS:Carriers of VKORC1 rs9923231 AG/GG genotypes required significantly higher warfarin dose (3.03?±?0.28 mg/day, 7.19 mg/day, respectively) than AA carriers (2.52?±?0.07 mg/day; P <?0.001). Carriers of CYP4F2 rs2108622 CT/TT genotypes required significantly higher warfarin dose (3.38?±?0.22 mg/day, 2.79?±?0.19 mg/day, respectively) than CC carriers (2.41?±?0.08 mg/day; P?<?0.001). However, the warfarin dose for carriers of NQO1 rs1800566 CT/TT genotypes (2.46?±?0.24 mg/day, 3.01?±?0.27 mg/day, respectively) was not significantly higher than that for the CC carriers (2.33?±?0.1 mg/day). The multiple linear regression model including genotypes and demographic characteristics, could explain 20.1% of individual variations in the daily stable warfarin dose in Sichuan Han Chinese. VKORC1 rs9923231 contributed most (15%) to the individual variations in daily stable warfarin dose, while CYP4F2 rs2108622 contributed least (3%). CONCLUSION:NQO1 rs1800566 is not a significant genetic factor of warfarin dose for Han Chinese, whereas VKORC1 rs9923231 and CYP4F2 rs2108622 are significant genetic factors, which could explain 15% and approximately 3% of individual variations in the daily stable warfarin dose respectively.

Dataset Information

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Publications

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets